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Terminal deoxynucleotidyl transferase (TdT) was one of the first DNA polymerases identified in mammals. 7 DNA polymerases have a vital role in replication, repair, and recombination of nucleic acids. To guide each of these events, the polymerase extends a primer using a DNA or RNA template. However, TdT possesses the unusual ability to incorporate nucleotides without a template. TdT uses only singlestranded DNA as the nucleic acid substrate, 7 thus, synthesizing DNA without a templating strand. Furthermore, TdT has a potential role in the development of certain forms of leukemia. TdT is expressed in immature, pre-B, and pre-T lymphoid cells. TdT is also used as a marker for neoplasms of precursor B-cell and T-cell origin. 8, 9 In addition to lymphoblastic neoplasms, TdT shows nuclear expression in other small round blue cell tumors, such as medulloblastoma, Ewing sarcoma, pediatric rhabdomyosarcoma, and small cell lung carcinoma. [10] [11] [12] and 65% express TdT. 34 On the basis of the frequent expression of Blymphoid lineage markers, zur Hausen et al. 31 proposed that the cell of origin of MCC might in fact not be the post-mitotic MC, but rather either a pro/pre-B cell or a pre-B cell. Thus, the stage of early B-cell development in which a MCV infection occurs could determine the phenotype and B-cell expression profile of subsequent MCC. 31 We used immunohistochemistry to evaluate the frequency of PAX5 and TdT expression in a large pool of MCC samples. We also sought to determine whether there is an association between the immunoexpression of PAX5 or TdT (or both) and the presence of MCV DNA and patient and tumor characteristics. The present study validates in a larger cohort the previous smaller scale studies on the connection between MCC and B-lymphoid lineage markers.
| PATIENTS AND METHODS
The MCV detection from paraffinized tumor blocks was performed in our previous study and is described in detail elsewhere. 36 In short, the presence of MCV DNA was analyzed from DNA extracted from representative deparaffinized tumor sections. Quantitation of MCV DNA was performed using real-time polymerase chain reaction (PCR). The relative DNA sequence copy number for each tissue sample was expressed as a ratio of MCV DNA to protein tyrosine phosphatase gamma receptor gene DNA. The sample was considered positive whenever MCV DNA copy number per reference gene was greater than 0.1. 37 Tissue microarray (TMA) blocks with 342 tissue cores were used for immunohistochemistry.
| Immunohistochemistry
Five-micrometer sections were cut from TMA blocks to create three slides from each TMA block; one was stained with hematoxylin and eosin to create a reference slide ( Figure 1 ) and one each was used for immunohistochemical staining of PAX5 and TdT. 
| Immunostaining evaluation
TMA spots were examined and evaluated for expression of PAX5 and
TdT by light microscopy. A grading system was used for the expres- 
| Morphological appearance
TMAs were evaluated by their cytomorphology to three categories;
classic, small cell variant and large cell/pleomorphic variant. 3 | RESULTS
| Statistical analysis

| Overview of the patients
Detailed patient clinical data are shown in Table 2 . Our cohort included 117 MCC patients, of which mean age was 78 years at the time of MCC diagnosis. Eighty-five (72%) of the patients were female.
Seven (6%) patients had been previously diagnosed with a hemato- 
| TdT and PAX5 expression in MCC
| DISCUSSION
We studied the immunoexpression of two lymphoid lineage markers (TdT and PAX5) from a large collection, 117 samples, of MCC tumor material. In this study, we attempted to validate in a larger cohort the with 93% and 70% positivity, respectively. Hence, at least part of the expression is dependent on the primary antibody used. Obviously, we acknowledge the limitation of using TMA cores in this study, which may have influenced the results. On the other hand, PAX5 expression is typically uniform, with only very few cases showing focal expression. 16 Considering the TdT expression, previous meta-analysis established 65%, 122/187, expression in MCC, 34 ranging from 21% 38 to 76%. 31 Our current expression rate of 32%, falls nicely in this range.
Simultaneous expression of both markers in the present study was MCC was first described in 1972 by Dr. Cyril Toker as "trabecular carcinoma" 41 and was soon recognized as a potential mimicker of malignant lymphoma. 42 The resemblance of these two malignancies is related to clinical and microscopic appearances. 42, 43 The immunohistochemical profile of MCC tumors is somewhat puzzling. The histology of MCC is typical of small round blue cell tumors, an entity that includes a wide variety of the following highly malignant tumors: the Ewing family of tumors, olfactory neuroblastoma, rhabdomyosarcoma, neuroblastoma, lymphoma, desmoplastic small cell tumor, osteosarcoma, small cell lung carcinoma, small cell melanoma, and mesenchymal chondrosarcoma. 44, 45 Apart from lymphoblastic neoplasms, TdT is expressed in other small round blue cell tumors. 46 In particular, another neuroendocrine carcinoma, small cell lung carcinoma, frequently shows high TdT expression. 12 Expression of PAX5 in cells other than B lymphocytes has rarely been reported. In small round blue cell tumors, PAX5 is mainly seen in MCC and small cell lung carcinoma. 16, 32 Expression of PAX5 has also been observed in certain types of poorly differentiated neuroendocrine carcinomas of the gastrointestinal and pancreatobiliary tracts. 47 However, the expression of PAX5 in MCC has been considered merely a reflection of cancerassociated dysregulation of protein expression than as an indication of lymphocytic origin of MCC. 32 The immunophenotypic features of MCC are typical of neuroendocrine carcinomas in other sites. Thus, MCC tumors express low-molecular-weight cytokeratins. 48, 49 Cytokeratin-20 is the most important and is employed in differential diagnostics, appearing in a dot-like pattern. 50, 51 Because of its neuroendocrine differentiation, MCC always stains positively for neuron-specific enolase, a general marker of neuroendocrine tumors. 52, 53 Other frequently expressed neuroendocrine markers include chromogranin-A, [54] [55] [56] synaptophysin, 56, 57 and microtubule-associated protein. 56, 58 With regard to lymphoproliferative markers, CD45 is consistently negative in MCC tumors, along with vimentin, CD5, and CD20. 59, 60 Three additional lymphoproliferative markers are nonetheless expressed in a significant proportion of MCCs, namely PAX5, CD99, and TdT. 42 However, recent research has revealed that the immunohistochemical features of MCC are to some extent different in MCV-positive and MCV-negative tumors. 61 Immunoglobulin expression seems to be restricted to MCV-positive tumors 31, 32 and has been postulated to be induced by MCV infection. 32 To conclude, we observed frequent TdT and PAX5 immunoexpression in MCC tumor samples. However, concomitant immunoexpression of these markers was scarce. TdT expression was statistically significantly associated with MCV positivity. The absence of a statistically significant association between tumor parameters and disease progression markers undermines the systemic use of these markers in clinical practice.
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